^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    HCCscreen™

    Company:
    Genetron Health
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    9ms
    Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population (PubMed, Zhonghua Gan Zang Bing Za Zhi)
    Furthermore, it may efficaciously detect liver cancer and precancerous diseases, with superior performance to AFP and AFP+ultrasound. Hence, HCCscreen has the potential to become an effective screening tool that is superior to existing screening methods for high-risk liver cancer populations.
    Journal
    |
    TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • AFP (Alpha-fetoprotein)
    |
    TP53 mutation • CTNNB1 mutation • TERT mutation
    |
    HCCscreen™
    over1year
    Application of the Multi-Omics Liquid Biopsy Method M2P-HCC in Early Liver Cancer Screening for High-Risk Individuals with Hepatitis B-Related Liver Cancer. (PubMed, Diagnostics (Basel))
    M2P-HCC liquid biopsy demonstrated good performance for early liver cancer screening in high-risk populations of Hepatitis B-related liver cancer, exhibiting better sensitivity than the combination of AFP and US.
    Journal • Liquid biopsy • Biopsy
    |
    AFP (Alpha-fetoprotein)
    |
    HCCscreen™
    over2years
    HCCscreen™: IVD approvals in 2023-2024 (Genetron Health)
    Investor Presentation
    Regulatory
    |
    HCCscreen™
    over2years
    HCCscreen™: Large-scale prospective study, registration trial enrollment to begin in 3Q 2022 (Genetron Health)
    Investor Presentation
    New trial
    |
    HCCscreen™
    over2years
    HCCscreen™: Initiation of registrational trial in 2022 (Genetron Health)
    Investor Presentation
    New trial
    |
    HCCscreen™
    over2years
    HCCscreen™: Large-scale prospective study enrollment to begin in late 2Q 2022 (Genetron Health)
    Investor Presentation
    New trial
    |
    HCCscreen™
    3years
    HCCscreen™: 4-5 sites clinical trials expected to be initiated in 1H 2022 (Genetron Health)
    Investor Presentation
    New trial
    |
    HCCscreen™
    3years
    Genetron Health’s liver cancer screening results and technology findings included in the Chinese Journal of Hepatology (Genetron Health Press Release)
    "Genetron Holdings Limited...today announced that the clinical results and technology findings of its early liver cancer screening product for hepatocellular carcinoma (HCC), HCCscreen™, were included in the October 2021 publication of Chinese Journal of Hepatology."
    Clinical
    |
    HCCscreen™